CTOs on the Move


 
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.89bio.com
  • 535 Mission Street 14th Floor
    San Francisco, CA USA 94105
  • Phone: 212.520.2765

Executives

Name Title Contact Details

Funding

89bio raised $60M on 10/25/2018
89bio raised $83.8M on 07/14/2020

Similar Companies

Centrillion Biosciences

Centrillion Biosciences is a leading genomic and bioinformatics solution provider.

TLC Biopharmaceuticals

TLC Biopharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arizona Benefit Plans

Arizona Benefit Plans is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enzyme by Design

A protein engineering startup passionate about developing safer cancer therapeutics

Dow Pharmaceutical Sciences

Dow Pharmaceutical Sciences is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.